选择性环氧合酶-2抑制剂在肿瘤放疗中的应用

doi:10.3760/cma.j.issn.1673-422X.2013.11.006

摘要/Abstract

摘要： 环氧合酶-2（COX-2）是花生四烯酸生物合成前列腺素的限速酶，在多种恶性肿瘤中高表达，在其发生、发展过程中发挥重要作用，而且与恶性肿瘤预后密切相关，目前已成为潜在的治疗靶点之一。实验研究发现选择性COX-2抑制剂可通过多种分子途径提高恶性肿瘤的放疗增敏性，对正常组织体现出放疗保护作用，是极具前景的放疗调节剂，其分子机制仍需继续深入研究。

关键词: font-family: 宋体, mso-ascii-font-family: Calibri, mso-ascii-theme-font: minor-latin, mso-fareast-theme-font: minor-fareast, mso-hansi-font-family: Calibri, mso-hansi-theme-font: minor-latin, mso-bidi-font-size: 11.0pt, mso-bidi-font-family: 'Times New Roman', mso-bidi-theme-font: minor-bidi, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA">环氧化酶, 肿瘤, 放射疗法

Abstract: Cyclooxygenase2 (COX2), the ratelimited enzyme that converts arachidonic acid into prostaglandin, has been found overexpression in many malignant tumors. The overexpression of COX2 plays an important role in tumor genesis and progression and is closely associated with tumor prognosis, so this enzyme has become one of the potential therapeutic targets. Experimental studies reveal that selective COX2 inhibitors can enhance the tumor radiosensitivity through a variety of molecular pathways and have a protective effect for normal tissues. Selective COX2 inhibitors are promising radiotherapy modifiers and the underlying molecular mechanisms still need to be further studied.

Key words: font-family: 'Calibri','sans-serif', mso-ascii-theme-font: minor-latin, mso-fareast-theme-font: minor-fareast, mso-hansi-theme-font: minor-latin, mso-bidi-font-size: 11.0pt, mso-bidi-font-family: 'Times New Roman', mso-bidi-theme-font: minor-bidi, mso-ansi-language: EN-US, mso-fareast-language: ZH-CN, mso-bidi-language: AR-SA, mso-fareast-font-family: 宋体">Cyclooxygenase2, Neoplasms, Radiotherapy

龙成, 姜永梅, 李国权. 选择性环氧合酶-2抑制剂在肿瘤放疗中的应用[J]. 国际肿瘤学杂志, 2013, 40(11): 820-823.

LONG Cheng, JIANG Yong-Mei, LI Guo-Quan. Application of selective cyclooxygenase-2 inhibitors in tumor radiotherapy[J]. Journal of International Oncology, 2013, 40(11): 820-823.

参考文献

［1］ Schetter AJ, Heegaard NH, Harris CC, et al. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis， 2010, 31 (1): 37-49. ［2］ Ke HL, Tu HP, Lin HH, et al. Cyclooxygenase-2 (COX-2) upregulation is a prognostic marker for poor clinical outcome of upper tract urothelial cancer. Anticancer Res， 2012,32(9):4111-4116. ［3］ Mestre F, Gutierrez A, Ramos R, et al. Expression of COX2 on ReedSternberg cells is an independent unfavorable prognostic factor in Hodgkin lymphoma treated with ABVD. Blood， 2012, 119(25):6072-6079. ［4］ Wang AH, Tian XY, Yu JJ, et al. Celecoxib radiosensitizes the human cervical cancer HeLa cell line via a mechanism dependent on reduced cyclooxygenase-2 and vascular endothelial growth factor C expression. Int J Med Res, 2012, 40(1):56-66. ［5］ Klenke FM, Abdollahi A, Bischof M, et al. Celecoxib enhances radiation response of secondary bone tumors of a human nonsmall cell lung cancer via antiangiogenesis in vivo. Strahlenther Onkol, 2011, 187(1):45-51. ［6］ Farnebo L, Jerhammar F, Ceder R, et al. Combining factors on protein and gene level to predict radioresponse in head and neck cancer cell lines. J Oral Pathol Med, 2011, 40(10):739-746. ［7］ Akutsu Y, Hanari N, Yusup G, et al. COX2 expression predicts resistance to chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol, 2011, 18(10):2946-2951. ［8］ Xiao Y, Teng Y, Zhang R, et al. Antitumor effect of the selective COX-2 inhibitor celecoxib on endometrial adenocarcinoma in vitro and in vivo. Oncol Lett, 2012, 4(6):1219-1224. ［9］ Che SM, Zhang XZ, Hou L, et al. Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis. Cancer Invest, 2010, 28(7):679-688. ［10］ Omahen DA. Augmentation of chemotherapytriggered glioma cell apoptosis by blockade of arachidonic acid metabolismthe potential role of ceramide accumulation. Med Hypotheses, 2011, 77(5):726-733. ［11］ Duan DP, Dang XQ, Wang KZ, et al. The cyclooxygenase-2 inhibitor NS398 inhibits proliferation and induces apoptosis in human osteosarcoma cells via downregulation of the survivin pathway. Oncol Rep, 2012, 28(5):1693-1700. ［12］孙权权, 袁亚维, 李刚, 等. shRNAmir慢病毒载体沉默COX-2对鼻咽癌细胞生长转移及放化疗敏感性的影响. 南方医科大学学报, 2011, 31(4):599-603. ［13］ Kang KB, Zhu C, Yong SK, et al. Enhanced sensitivity of celecoxib in human glioblastoma cells: Induction of DNA damage leading to p53dependent G1 cell cycle arrest and autophagy. Mol Cancer, 2009, 8:66. ［14］徐慧婷, 于世英, 翁丹卉, 等. RNA干扰抑制环氧化酶2表达对宫颈癌HeLa细胞增殖的影响. 华中科技大学学报, 2009, 38(1):59-63. ［15］ Li G, Xie B, Li X, et al. Downregulation of survivin and hypoxiainducible factor1α by βelemene enhances the radiosensitivity of lung adenocarcinoma xenograft. Cancer Biother Radiopharm, 2012, 27(1):56-64. ［16］ Liu J, Zhang J, Wang X. HIF-1 and NDRG2 contribute to hypoxiainduced radioresistance of cervical cancer Hela cells. Exp Cell Res, 2010, 316(12):1985-1993. ［17］ Semenza GL. Hypoxiainducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci, 2012, 33(4): 207-214. ［18］ Stasinopoulos I, O′Brien DR, Bhujwalla ZM. Inflammation, but not hypoxia,mediated HIF1alpha activation depends on COX-2. Cancer Biol Ther, 2009, 8(1):31-35. ［19］ Zhang YF, Ruan LH, Zhao XQ. Effects of COX-2 inhibitor celecoxib on expressions of VEGF, bFGF and TGFβ mRNA in acute leukemia cells. Zhongguo Shi Yan Xue Ye Xue Za Zhi, 2012,20(5):1086-1089. ［20］ Chen J, Ran Y, Hong C, et al. Anticancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expressing COX-2 oncoprotein. Cytotechnology, 2010, 62(5):431-438. ［21］ Markosvan N, Chen EP, Ndong VN, et al. Deletion of cyclooxygenase-2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.Carcinogenesis, 2011, 32(10):1441-1449. ［22］ Hunter NR, Valdecanas D, Liao Z, et al. Mitigation and treatment of radiationinduced thoracic injury with a cyclooxygenase-2 inhibitor, Celecoxib. Int J Oncol Biol Phys, 2013, 85(2):472-476. ［23］ Khayyal MT, El Ghazaly MA, El Hazek RM, et al. The effects of celecoxib, a COX-2 selective inhibitor, on acute inflammation induced in irradiated rats. Inflammopharmacology, 2009, 17(5):255-266. ［24］ Yang HJ, Youn H, Seong KM, et al. Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation(IR)induced pulmonary inflammation. Biochem Pharmacol, 2011, 82(5):524-534. ［25］ Chai Y, Calaf GM, Zhou H, et al. Radiation induced COX-2 expression and mutagenesis at non targeted lung tissues of gpt delta transgenic mice. Br J Cancer, 2013, 108(1):91-98. ［26］ Hofer M, Pospisil M, Hoferova Z, et al. Stimulatory action of cyclooxygenase inhibitors on hematopoiesis:a Review. Molecules, 2012, 17(5):5615-5625.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝. 癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志. 宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.